Longitudinal Humoral Response After SARS-CoV-2 Vaccination in Ocrelizumab-Treated MS Patients
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Multiple Sclerosis and Related Disorders
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Longitudinal humoral response after SARS-CoV-2 vaccination in ocrelizumab treated MS patients: To wait and repopulate?
Mult Scler Relat Disord 2021 Nov 23;57(xx)103416, ZLE van Kempen, L Wieske, EW Stalman, LYL Kummer, PJ van Dam, AG Volkers, L Boekel, AA Toorop, EMM Strijbis, SW Tas, GJ Wolbink, M Löwenberg, C van Sandt, A Ten Brinke, NJM Verstegen, M Steenhuis, TW Kuijpers, SM van Ham, T Rispens, F Eftimov, J KillesteinFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.